GSA Capital Partners’s ImmunityBio IBRX Stock Holding History

GSA Capital Partners’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.02M	Buy	116,922 +60,262	+106%	+$456K	0.06%	493
2026 Q1	$435K	Buy	56,660 +40,700	+255%	+$279K	0.03%	1002
2025 Q4	$32K	Buy	+15,960	New	+$36.2K	﹤0.01%	1590
2025 Q1	–	Sell	-41,031	Closed	-$105K	–	1837
2024 Q4	$105K	Sell	41,031 -66,954	-62%	-$279K	0.01%	1509
2024 Q3	$402K	Buy	107,985 +80,318	+290%	+$372K	0.03%	1058
2024 Q2	$175K	Buy	+27,667	New	+$182K	0.01%	1477
2023 Q1	–	Sell	-22,043	Closed	-$112K	–	1678
2022 Q4	$112K	Buy	+22,043	New	+$121K	0.01%	1291
2022 Q3	–	Sell	-84,884	Closed	-$316K	–	1682
2022 Q2	$316K	Buy	84,884 +1,680	+2%	+$6.75K	0.05%	789
2022 Q1	$467K	Sell	83,204 -46,056	-36%	-$283K	0.06%	583
2021 Q4	$786K	Buy	+129,260	New	+$971K	0.1%	323
2020 Q2	–	Sell	-13,119	Closed	-$38K	–	841
2020 Q1	$38K	Buy	+13,119	New	+$65.7K	0.01%	969

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

GSA Capital Partners's IBRX Position: Q2 2026 in Review

GSA Capital Partners increased its ImmunityBio (IBRX) stake by 106% in Q2 2026, buying an estimated $456K and bringing the position to 116,922 shares worth $1.02M. The position accounts for 0.06% of the portfolio, ranked #493.

GSA Capital Partners first reported a position in IBRX in Q1 2020 and has held it in 11 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

GSA Capital Partners held 116,922 shares of ImmunityBio worth $1.02M as of Q2 2026.
GSA Capital Partners bought 60,262 ImmunityBio shares in Q2 2026, an estimated $456K.
ImmunityBio made up 0.06% of GSA Capital Partners's portfolio in Q2 2026, its #493 holding.
GSA Capital Partners first reported a position in ImmunityBio in Q1 2020 and has held it in 11 quarters since.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.